the "Wolverine peptide"
1989 (isolation) / 1991-1993 (naming, first synthesis, PLIVA licensing)
Officially, the "BPC" in BPC-157 stands for "Body Protection Compound" — but the Croatian scientists who isolated it during Yugoslavia's violent collapse privately called it "Boze Pomozi," meaning "God help us."
In 1975, a second-year medical student at the University of Zagreb named Predrag Sikiric had a hunch: if the stomach lining survives being bathed in its own corrosive acid every single day, then something in gastric juice must be actively protecting it. Chasing that idea to an actual compound took until 1989, and the sourcing was anything but glamorous. Teams collected acidic stomach fluid discarded as medical waste from Zagreb gastroenterology clinics and emergency rooms, and visited pig slaughterhouses to scrape gastric contents from the discarded GI tract; Sikiric has told journalists the fluid sometimes contained the remains of rats the pigs had caught and eaten. The bottles were hauled back to a shared departmental refrigerator, where they occasionally cracked and stank up the building.
The name is where the story gets genuinely strange. The team first nicknamed it "Substancija Boze Pomozi" — roughly "God-help-us substance" — a dark joke aimed at both its seemingly remarkable protective powers and the political chaos of Yugoslavia's breakup. That collapsed into the dual-meaning acronym BPC: officially "Body Protection Compound" for the journals, unofficially "Boze Pomozi Croatia" ("God Help Croatia") for the researchers living through it. The trailing 157 is usually explained as a nod to July 15 (15/7) — a date rumored across Croatia in 1990 to be when independence would be declared, though the country actually declared it on 25 June 1991, a full year later, with war following almost immediately.
By 1993 the fragment had been synthesized as a stable 15-amino-acid peptide, and Zagreb's PLIVA licensed it, teaming with the American firm Parke-Davis to run early human trials for ulcerative colitis. The results were mixed — a second trial showed a positive trend that never reached statistical significance — and after GlaxoSmithKline bought PLIVA's research arm in 2006, the compound was quietly shelved, with rights reverting to Sikiric in 2009. His lab has since published over 150 papers on it, almost entirely in animals and cell cultures.
Then, around 2010, bodybuilders discovered it online, began ordering it from Chinese peptide suppliers, and started reporting startlingly fast recovery from joint and soft-tissue injuries. The "Wolverine" nickname bubbled up from that community around 2019-2020 — most precisely for the "Wolverine stack" of BPC-157 paired with TB-500, though people now toss it around loosely for BPC-157 all on its own.
The big-picture story holds up against a 2026 Pulitzer-backed investigation, but a few flourishes are softer than they sound: the vivid "rats the pigs had eaten" detail is Sikiric's own decades-later recollection rather than independently confirmed fact, the catchy "157 = July 15" rumor dates to 1990 (not the actual June 1991 independence declaration), and the "Wolverine" nickname is internet folklore that most precisely tags the BPC-157 + TB-500 stack, not the peptide alone.
BPC-157 still isn't approved for human use anywhere, and in the US it was recently pulled from the list of substances compounding pharmacies are allowed to prepare — though a 2026 FDA advisory committee is now weighing whether to let them sell it and six other unapproved peptides under physician oversight, a push partly fueled by RFK Jr.'s Make America Healthy Again movement. For now it moves through a large "research-use-only" gray market, popular off-label with biohackers, athletes, and bodybuilders for tendon, ligament, and gut-healing claims. And it remains genuinely contested, not just under-studied: no receptor has been identified, the full parent-protein sequence was never published, human trial data is essentially unpublished, and credentialed skeptics like University of Michigan chemist Anna Mapp and former PLIVA adviser Michael Parnham openly question whether "BPC" was ever a single, well-defined natural substance at all.
